MY169349A - Biodegradable, semi-crystalline, phase separated, thermoplastic multi-block copolymers for controlled release of biologically active compounds - Google Patents

Biodegradable, semi-crystalline, phase separated, thermoplastic multi-block copolymers for controlled release of biologically active compounds

Info

Publication number
MY169349A
MY169349A MYPI2014700136A MYPI2014700136A MY169349A MY 169349 A MY169349 A MY 169349A MY PI2014700136 A MYPI2014700136 A MY PI2014700136A MY PI2014700136 A MYPI2014700136 A MY PI2014700136A MY 169349 A MY169349 A MY 169349A
Authority
MY
Malaysia
Prior art keywords
biodegradable
crystalline
semi
polymer
biologically active
Prior art date
Application number
MYPI2014700136A
Other languages
English (en)
Inventor
Rob Steendam
Theodorus Adrianus Cornelius Flipsen
Christine Hiemstra
Johan Zuidema
Original Assignee
Innocore Tech B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innocore Tech B V filed Critical Innocore Tech B V
Publication of MY169349A publication Critical patent/MY169349A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C08G63/668—Polyesters containing oxygen in the form of ether groups derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/672—Dicarboxylic acids and dihydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/002—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from unsaturated compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L101/00—Compositions of unspecified macromolecular compounds
    • C08L101/16—Compositions of unspecified macromolecular compounds the macromolecular compounds being biodegradable
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L87/00—Compositions of unspecified macromolecular compounds, obtained otherwise than by polymerisation reactions only involving unsaturated carbon-to-carbon bonds
    • C08L87/005—Block or graft polymers not provided for in groups C08L1/00 - C08L85/04
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/38—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing oxygen in addition to the ether group
    • C08G2650/42—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing oxygen in addition to the ether group containing orthoester groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
MYPI2014700136A 2011-07-22 2012-07-23 Biodegradable, semi-crystalline, phase separated, thermoplastic multi-block copolymers for controlled release of biologically active compounds MY169349A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11174987 2011-07-22

Publications (1)

Publication Number Publication Date
MY169349A true MY169349A (en) 2019-03-21

Family

ID=46704994

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014700136A MY169349A (en) 2011-07-22 2012-07-23 Biodegradable, semi-crystalline, phase separated, thermoplastic multi-block copolymers for controlled release of biologically active compounds

Country Status (19)

Country Link
US (2) US20140199385A1 (cg-RX-API-DMAC7.html)
EP (1) EP2734573B1 (cg-RX-API-DMAC7.html)
JP (2) JP6174023B2 (cg-RX-API-DMAC7.html)
KR (1) KR101889586B1 (cg-RX-API-DMAC7.html)
CN (1) CN103827177B (cg-RX-API-DMAC7.html)
AU (1) AU2012287577B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014001441A2 (cg-RX-API-DMAC7.html)
CA (1) CA2842514C (cg-RX-API-DMAC7.html)
CL (1) CL2014000159A1 (cg-RX-API-DMAC7.html)
CO (1) CO7020923A2 (cg-RX-API-DMAC7.html)
ES (1) ES2899701T3 (cg-RX-API-DMAC7.html)
IL (1) IL230606B (cg-RX-API-DMAC7.html)
MX (1) MX362941B (cg-RX-API-DMAC7.html)
MY (1) MY169349A (cg-RX-API-DMAC7.html)
PH (1) PH12014500192A1 (cg-RX-API-DMAC7.html)
RU (2) RU2662818C2 (cg-RX-API-DMAC7.html)
UA (1) UA112192C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013015685A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201400846B (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012287577B2 (en) * 2011-07-22 2017-02-16 InnoCore Technologies Holding B.V. Biodegradable, semi-crystalline, phase separated, thermoplastic multi block copolymers for controlled release of biologically active compounds
EP2987484B1 (en) * 2013-04-18 2018-12-19 Shandong Luye Pharmaceutical Co., Ltd. Goserelin sustained release microsphere pharmaceutical composition
JO3394B1 (ar) 2014-07-04 2019-10-20 Osteo Pharma B V تركيبات ومنتجات للاستعمال في علاج كسور وعيوب العظام
CN105273154A (zh) * 2014-07-24 2016-01-27 允友成(宿迁)复合新材料有限公司 一种可降解聚乳酸基水性乳液及其制备方法
CN105273153A (zh) * 2014-07-24 2016-01-27 允友成(宿迁)复合新材料有限公司 一种可降解生物基水性乳液及其制备方法
CA2957966C (en) * 2014-08-14 2021-11-30 Brown University Compositions for stabilizing and delivering proteins
WO2016075304A1 (en) 2014-11-14 2016-05-19 University College Cork - National University Of Ireland, Cork Delivery of igf-1 in myocardial infarction
KR102009972B1 (ko) * 2015-11-25 2019-10-21 주식회사 엘지화학 양친성 고분자
KR102001614B1 (ko) * 2015-11-25 2019-07-18 주식회사 엘지화학 양친성 고분자
CN108410295B (zh) * 2015-12-22 2020-09-25 江门市蓬江区巨匠涂料化工有限公司 抗菌耐划伤漆
JP7665280B2 (ja) 2015-12-22 2025-04-21 アクセス・バスキュラー・インコーポレイテッド 高強度生体材
KR101999947B1 (ko) * 2016-06-16 2019-07-15 주식회사 엘지화학 양친성 고분자
WO2017217813A1 (ko) * 2016-06-16 2017-12-21 주식회사 엘지화학 양친성 고분자
JP6800242B2 (ja) * 2016-06-16 2020-12-16 エルジー・ケム・リミテッド 両親媒性トリブロック高分子
EP3576771B1 (en) 2017-01-31 2022-03-09 Veru Inc. Compositions and methods for long term release of ganadotropin-releasing hormone (gnrh) antagonists
CN109701081B (zh) * 2017-07-15 2019-12-06 深圳市立心科学有限公司 可吸收的生物医用复合材料及其制备方法
KR20240146109A (ko) * 2017-10-04 2024-10-07 패션 케미칼즈 게엠베하 운트 코. 카게 신규한 폴리락트산의 에스테르 및 이의 조성물
RU2020132481A (ru) * 2018-03-30 2022-05-04 Торэй Индастриз, Инк. Биоразлагаемый блок-сополимер
CN108387664B (zh) * 2018-07-03 2020-06-23 中国食品药品检定研究院 人血白蛋白分子大小分布超高效液相色谱测定方法
WO2020071912A1 (en) 2018-10-02 2020-04-09 Innocore Technologies B.V. Extended release formulations of human chorionic gonadotropin (hcg)
JP2022514368A (ja) * 2018-12-19 2022-02-10 アクセス・バスキュラー・インコーポレイテッド 放出制御用高強度多孔質材料
CN114174574A (zh) * 2019-03-28 2022-03-11 Pk医疗公司 多组分热塑性产品
US20210017329A1 (en) * 2019-07-19 2021-01-21 Evonik Operations Gmbh Multi-block shape memory bioresorbable polymers
US20220331258A1 (en) 2019-10-01 2022-10-20 Allergan Sales, Llc Poly-Dioxanone Multi-Block Copolymer for Ocular Protein Delivery
JP7737981B2 (ja) 2019-10-01 2025-09-11 イノコア テクノロジーズ ホールディング ビー．ブイ． 生分解性の相分離した熱可塑性マルチブロックコポリマー
US11819576B2 (en) * 2019-10-31 2023-11-21 Evonik Operations Gmbh Process for preparing nano-or microparticles comprising a carrier-polymer and one or more biologically active ingredients
WO2021086188A1 (en) 2019-11-01 2021-05-06 Innocore Technologies B.V. Dosage form for extended release of an antibody or large protein
US20230055790A1 (en) * 2019-12-12 2023-02-23 Massachusetts Eye And Ear Infirmary Melt-extrudable 3d printing inks
WO2021168170A1 (en) * 2020-02-21 2021-08-26 Natureworks Llc Cosmetic compositions containing low molecular weight amorphous grade polylactic acid resin
JP2023522134A (ja) * 2020-04-10 2023-05-26 サイエンチュア， インコーポレイテッド 長時間作用型アポモルフィン製剤、およびその治療送達用のインジェクター
CA3180971A1 (en) 2020-04-22 2021-10-28 Scienture, Inc. Long-acting bupivacaine microsphere formulations
CN111484635B (zh) * 2020-06-10 2023-09-12 杭州铭善生物科技有限公司 一种温敏性水凝胶材料的改性方法、改性温敏性水凝胶材料和生物3d打印墨水
CN112336689B (zh) * 2020-10-30 2022-06-28 浙江大学衢州研究院 一种结晶性嵌段共聚物胶束制备多重Pickering乳液的方法
WO2022159658A1 (en) * 2021-01-22 2022-07-28 University Of Connecticut Synthetic artificial stem cells (sasc)
US12186722B2 (en) 2022-02-07 2025-01-07 Honeywell Federal Manufacturing & Technologies, Llc Porous polysiloxane microspheres
CN114737276B (zh) * 2022-03-11 2023-02-07 北京朗净汇明生物科技有限公司 一种耐热抗水解型聚乳酸纤维及其制备方法
CA3246070A1 (en) 2022-03-17 2023-09-21 Polyvation B.V. BIODEGRADABLE THERMOPLASTIC MULTIBLOCK COPOLYMERS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4429080A (en) 1982-07-01 1984-01-31 American Cyanamid Company Synthetic copolymer surgical articles and method of manufacturing the same
US5066772A (en) 1987-12-17 1991-11-19 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US5133739A (en) 1990-02-06 1992-07-28 Ethicon, Inc. Segmented copolymers of ε-caprolactone and glycolide
CN1037612C (zh) * 1992-07-20 1998-03-04 中国科学院化学研究所 热致形状可回复性多嵌段聚合物材料
US5236444A (en) 1992-10-27 1993-08-17 United States Surgical Corporation Absorbable polymers and surgical articles made therefrom
RU2185393C2 (ru) * 1993-01-06 2002-07-20 Кинертон Лимитед Сложный полиэфир и конъюгат на его основе
US5403347A (en) 1993-05-27 1995-04-04 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
US5711958A (en) 1996-07-11 1998-01-27 Life Medical Sciences, Inc. Methods for reducing or eliminating post-surgical adhesion formation
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6211249B1 (en) 1997-07-11 2001-04-03 Life Medical Sciences, Inc. Polyester polyether block copolymers
WO1999042147A1 (en) 1998-02-23 1999-08-26 Massachusetts Institute Of Technology Biodegradable shape memory polymers
US8158143B2 (en) 2000-07-14 2012-04-17 Helmholtz-Zentrum Geesthacht Zentrum Fuer Material- Und Kuestenforschung Gmbh Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect
EP1382628A1 (en) * 2002-07-16 2004-01-21 Polyganics B.V. Biodegradable phase separated segmented/block co-polyesters
EP1555278A1 (en) * 2004-01-15 2005-07-20 Innocore Technologies B.V. Biodegradable multi-block co-polymers
US20090004243A1 (en) * 2007-06-29 2009-01-01 Pacetti Stephen D Biodegradable triblock copolymers for implantable devices
AU2012287577B2 (en) * 2011-07-22 2017-02-16 InnoCore Technologies Holding B.V. Biodegradable, semi-crystalline, phase separated, thermoplastic multi block copolymers for controlled release of biologically active compounds

Also Published As

Publication number Publication date
AU2012287577A1 (en) 2014-03-13
CA2842514C (en) 2018-12-18
RU2662818C2 (ru) 2018-07-31
IL230606A0 (en) 2014-03-31
KR101889586B1 (ko) 2018-09-20
CN103827177B (zh) 2016-02-10
MX362941B (es) 2019-02-27
MX2014000891A (es) 2015-05-11
US20140199385A1 (en) 2014-07-17
IL230606B (en) 2019-07-31
ES2899701T3 (es) 2022-03-14
NZ620392A (en) 2016-02-26
KR20140048296A (ko) 2014-04-23
WO2013015685A1 (en) 2013-01-31
BR112014001441A2 (pt) 2019-05-14
CA2842514A1 (en) 2013-01-31
JP2017141477A (ja) 2017-08-17
CN103827177A (zh) 2014-05-28
JP6472836B2 (ja) 2019-02-20
EP2734573A1 (en) 2014-05-28
ZA201400846B (en) 2016-08-31
EP2734573B1 (en) 2021-09-08
PH12014500192A1 (en) 2014-03-24
RU2014102900A (ru) 2015-08-27
US10300019B2 (en) 2019-05-28
CL2014000159A1 (es) 2014-08-29
AU2012287577B2 (en) 2017-02-16
UA112192C2 (uk) 2016-08-10
JP6174023B2 (ja) 2017-08-02
RU2018125698A (ru) 2019-03-13
CO7020923A2 (es) 2014-08-11
US20180085318A1 (en) 2018-03-29
JP2014521762A (ja) 2014-08-28

Similar Documents

Publication Publication Date Title
MY169349A (en) Biodegradable, semi-crystalline, phase separated, thermoplastic multi-block copolymers for controlled release of biologically active compounds
WO2012166923A3 (en) Drug loaded polymeric nanoparticles and methods of making and using same
WO2013116804A3 (en) Polymeric biomaterials derived from phenolic monomers and their medical uses
EA201170038A1 (ru) Загруженные лекарственным средством полимерные наночастицы и способы их получения и применения
WO2012005594A3 (en) Biodegradable phase separated segmented multi block co-polymers and release of biologically active polypeptides
WO2011109384A3 (en) Biodegradable polymers for lowering intraocular pressure
CY1116785T1 (el) Χαμηλης αποτομης αποδεσμευσης πολυ-(γαλακτιδιο/γλυκολιδιο) και μεθοδοι παραγωγης πολυμερων
EP2719714A4 (en) LACTID COPOLYMER, METHOD FOR ITS PREPARATION AND RESIN COMPOSITION THEREWITH
MX2009014279A (es) Cadenas laterales de ester de fenilo para incrementar la resortividad polimerica.
WO2011057225A3 (en) Self-assembled particles from zwitterionic polymers and related methods
EP2812267A4 (en) METHOD AND STEREO SYSTEM FOR FACILITATING THE LOADING OF AGRICULTURAL MATERIAL FROM A VEHICLE
WO2008137235A3 (en) Implantable medical devices fabricated from polymers with radiopaque groups
EP2395048A3 (en) Polymers compositions including an antioxidant
MX2014004862A (es) Formulaciones de polimero acrilico.
BR112013027161A2 (pt) derivado reticulado de ácido hialurônico, processo de preparação do derivado, derivado reticulado de ácido hialurônico e uso do derivado reticulado
WO2009015336A3 (en) Controlled release interferon drug products and treatment of hcv infection using same
WO2008152115A3 (en) Drug-releasing polyelectrolyte coating, method for forming a drug-releasing polyelectrolyte coating, and implantable device
EP2666797A4 (en) OLEFIN BLOCK COPOLYMER AND MANUFACTURING METHOD THEREFOR
WO2010120389A8 (en) Polymeric drug delivery systems and processes for producing such systems
HK1201213A1 (en) Nonaqueous compositions for bone hemostasis, and methods for their use and manufacture
WO2012050879A3 (en) Methods for processing microspheres, microspheres processed thereby, and uses thereof
WO2013013038A3 (en) Doping agents and polymeric compositions thereof for controlled drug delivery
EP4242240A3 (en) Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
WO2012174543A3 (en) Phosphonium-containing polyelectrolytes for nonviral gene delivery
BR112015009453A2 (pt) composição farmacêutica estável de peg-interferona alfa-2b